FY2025 EPS Estimates for Certara Cut by Leerink Partnrs

Certara, Inc. (NASDAQ:CERT - Free Report) - Stock analysts at Leerink Partnrs reduced their FY2025 EPS estimates for shares of Certara in a research note issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.28 per share for the year, down from their previous forecast of $0.29. The consensus estimate for Certara's current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Certara's FY2028 earnings at $0.44 EPS.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The firm's quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS.

A number of other research analysts also recently issued reports on CERT. Morgan Stanley initiated coverage on shares of Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 target price on the stock. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. JMP Securities restated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Robert W. Baird upped their target price on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Finally, KeyCorp increased their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $15.71.

Certara Stock Performance

Certara stock opened at $11.50 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. Certara has a 1 year low of $8.64 and a 1 year high of $16.93. The company has a market cap of $1.87 billion, a PE ratio of -575.00 and a beta of 1.43. The company's 50-day moving average is $11.46 and its two-hundred day moving average is $11.86.

Institutional Trading of Certara

A number of hedge funds have recently modified their holdings of CERT. ArrowMark Colorado Holdings LLC raised its holdings in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after buying an additional 3,861,674 shares during the period. Ameriprise Financial Inc. raised its holdings in Certara by 864.0% during the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock worth $40,253,000 after buying an additional 3,387,590 shares during the period. Mackenzie Financial Corp acquired a new stake in Certara during the 4th quarter worth approximately $17,852,000. Brown Brothers Harriman & Co. raised its holdings in Certara by 63.8% during the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock worth $40,668,000 after buying an additional 1,487,998 shares during the period. Finally, ExodusPoint Capital Management LP acquired a new stake in Certara during the 4th quarter worth approximately $11,542,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.